IPO - SOLENO THERAPEUTICS INC

Form Type: 424B5

Filing Date: 2025-07-10

Corporate Action: Ipo

Type: New

Accession Number: 000119312525157301

Filing Summary: Soleno Therapeutics Inc. is offering $200,000,000 in shares of its common stock, with a par value of $0.001 per share, under the registration statement filed with the SEC. The company's common stock is listed on the Nasdaq Capital Market under the symbol 'SLNO'. As of July 9, 2025, the last reported sale price for the common shares was $88.49. The offering is aimed at providing funds to support the commercialization of their approved lead product candidate, VYKAT™ XR, for treating hyperphagia in patients with Prader-Willi syndrome (PWS). The preliminary prospectus supplement details the risks related to the investment and outlines underwriters' efforts to account for expenses associated with the offering. Potential additional shares could be purchased by underwriters amounting to $30,000,000. The document outlines the use of proceeds from the offering, mentioning commercialization in the US and regulatory activities in the EU, emphasizing significant unmet medical needs and potential market opportunities for their product. Investing in their common stock is noted to involve a high degree of risk due to potential dilution and other factors affecting stockholder value.